TRVN
Price:
$1.69
Market Cap:
$1.44M
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and...[Read more]
Industry
Biotechnology
IPO Date
2014-01-31
Stock Exchange
NASDAQ
Ticker
TRVN
According to Trevena, Inc.’s latest financial reports and current stock price. The company's current ROE is 392.47%. This represents a change of 2.13% compared to the average of 17.59% of the last 4 quarters.
The mean historical ROE of Trevena, Inc. over the last ten years is -51.66%. The current 392.47% ROE has changed -859.67% with respect to the historical average. Over the past ten years (40 quarters), TRVN's ROE was at its highest in in the December 2023 quarter at 215.62%. The ROE was at its lowest in in the September 2023 quarter at -223.44%.
Average
-51.66%
Median
-76.65%
Minimum
-344.04%
Maximum
526.17%
Discovering the peaks and valleys of Trevena, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 334.62%
Maximum Annual ROE = 526.17%
Minimum Annual Increase = -252.94%
Minimum Annual ROE = -344.04%
Year | ROE | Change |
---|---|---|
2023 | 526.17% | -252.94% |
2022 | -344.04% | 334.62% |
2021 | -79.16% | 180.50% |
2020 | -28.22% | -69.75% |
2019 | -93.28% | 25.83% |
2018 | -74.13% | -64.27% |
2017 | -207.50% | 58.32% |
2016 | -131.07% | 271.27% |
2015 | -35.30% | -29.54% |
2014 | -50.10% | -15.98% |
The current ROE of Trevena, Inc. (TRVN) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
34.32%
5-year avg
-3.71%
10-year avg
-51.66%
Trevena, Inc.’s ROE is greater than AcelRx Pharmaceuticals, Inc. (-48.62%), greater than Lipocine Inc. (-38.58%), greater than Verastem, Inc. (-133.02%), less than vTv Therapeutics Inc. (638.41%), less than Nabriva Therapeutics plc (6.00%),
Company | ROE | Market cap |
---|---|---|
-48.62% | $14.58M | |
-38.58% | $32.57M | |
-133.02% | $156.95M | |
638.41% | $34.06M | |
6.00% | $4.55M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevena, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Trevena, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Trevena, Inc.'s ROE?
How is the ROE calculated for Trevena, Inc. (TRVN)?
What is the highest ROE for Trevena, Inc. (TRVN)?
What is the 3-year average ROE for Trevena, Inc. (TRVN)?
What is the 5-year average ROE for Trevena, Inc. (TRVN)?
How does the current ROE for Trevena, Inc. (TRVN) compare to its historical average?